Enrichment designs using placebo nonresponders

被引:4
|
作者
Benda, Norbert [1 ,2 ]
Haenisch, Britta [1 ,3 ,4 ]
机构
[1] Fed Inst Drugs & Med Devices BfArM, Res Dept, Bonn, Germany
[2] Univ Med Ctr Gottingen, Dept Med Stat, Gottingen, Germany
[3] German Ctr Neurodegenerat Dis DZNE, Populat Hlth Sci, Bonn, Germany
[4] Univ Bonn, Ctr Translat Med, Bonn, Germany
关键词
drug approval; enrichment design; placebo response; sequential parallel design; MAJOR DEPRESSIVE DISORDER; DOUBLE-BLIND; CLINICAL-TRIALS; ZIPRASIDONE MONOTHERAPY; 12-WEEK; SYMPTOMS; EFFICACY; OUTCOMES; THERAPY;
D O I
10.1002/pst.1992
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Enrichment designs that select placebo nonresponders have gained much attention during the last years in areas with high placebo response rates, eg, in depression. Proposals were made that re-randomize patients who did not respond to placebo during a first study phase as the sequential parallel design (SPD). This design uses in a second phase an enriched patient population where the treatment effect is expected to be more pronounced. This may be problematic if an effect in the overall population is claimed. Proposals were made to combine the treatment effects in the overall population from study phase 1 and the enriched population from study phase 2, alleviating but not solving the issue of a potential selection bias. This paper shows how this bias corresponding to the effect difference between the overall population and the enriched population depends on the variability of a potential subject-by-treatment interaction. Sample sizes are given, which lead to a significant result in the combining test with a given probability if actually the average effect in the overall population is zero. If, on the other hand, no subject-by-treatment interaction is given, the enrichment is shown to be inefficient. We conclude that enrichment designs using placebo nonresponders are not able to claim a positive average effect in the overall population if a subject-by-treatment interaction cannot be excluded. It cannot be used to demonstrate positive efficacy in the overall population in a pivotal phase III trial but may be used in early phases to demonstrate varying treatment effects between patients.
引用
收藏
页码:303 / 314
页数:12
相关论文
共 50 条
  • [21] New insights into adaptive enrichment designs
    Antognini, Alessandro Baldi
    Frieri, Rosamarie
    Zagoraiou, Maroussa
    STATISTICAL PAPERS, 2023, 64 (04) : 1305 - 1328
  • [22] Adaptive Enrichment Designs in Clinical Trials
    Thall, Peter F.
    ANNUAL REVIEW OF STATISTICS AND ITS APPLICATION, VOL 8, 2021, 2021, 8 : 393 - 411
  • [23] Enrichment Clinical Trial Designs Do Not Decrease the Placebo Response Rate in Pediatric Studies: A Systematic Review of Triptan Trials
    Richer, L.
    Neilson, J.
    CEPHALALGIA, 2013, 33 (S8) : 35 - 35
  • [24] DOUBLY RANDOMIZED DELAYED-START DESIGN FOR ENRICHMENT STUDIES WITH RESPONDERS OR NONRESPONDERS
    Liu, Qing
    Lim, Pilar
    Singh, Jaskaran
    Lewin, David
    Schwab, Barry
    Kent, Justine
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (04) : 737 - 757
  • [25] RESPONDERS, NONRESPONDERS, AND PLACEBO RESPONDERS AMONG CHILDREN WITH ATTENTION-DEFICIT DISORDER - IMPORTANCE OF A BLINDED PLACEBO EVALUATION
    ULLMANN, RK
    SLEATOR, EK
    CLINICAL PEDIATRICS, 1986, 25 (12) : 594 - 599
  • [26] Neural mechanisms mediating the effects of expectation in visceral placebo analgesia: An fMRI study in healthy placebo responders and nonresponders
    Elsenbruch, Sigrid
    Kotsis, Vassilios
    Benson, Sven
    Rosenberger, Christina
    Reidick, Daniel
    Schedlowski, Manfred
    Bingel, Ulrike
    Theysohn, Nina
    Forsting, Michael
    Gizewski, Elke R.
    PAIN, 2012, 153 (02) : 382 - 390
  • [27] New designs for placebo controlled studies
    Carpenter, William T.
    Kelly, Deanna
    Boggs, Doug
    McMahon, Robert
    Davis, John
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S58 - S58
  • [28] Trial designs and exploration of the placebo response
    Dieppe, Paul
    COMPLEMENTARY THERAPIES IN MEDICINE, 2013, 21 (02) : 105 - 108
  • [29] Timing of the interim analysis in adaptive enrichment designs
    Benner, Laura
    Kieser, Meinhard
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2018, 28 (04) : 622 - 632
  • [30] Adaptive Enrichment Designs for Stroke Clinical Trials
    Rosenblum, Michael
    Hanley, Daniel F.
    STROKE, 2017, 48 (07) : 2021 - 2025